Outsourcing-pharma2d
Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Novo Nordisk's Ozempic gets FDA approval for kidney disease
Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...
FiercePharma13d
Novo's semaglutide among 2nd batch of drugs selected for IRA price negotiations
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial
Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
Mena FN13d
Novo Nordisk A/S: Semaglutide 7.2 Mg S.C. Achieved 20.7% Weight Loss In The STEP UP Obesity Trial, And 18.7% Regardless Of Treatment Adherence
Novo Nordisk has initiated two trials investigating the efficacy of semaglutide 7.2mg, STEP UP and STEP UP T2D. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group ...
Why Eli Lilly Stock Topped the Market Today
On Friday morning, Novo Nordisk unveiled the latest results from a clinical trial of CagriSema, an investigational drug ...
MedCity News5d
Novo Nordisk Obesity Drug Shows 22% Weight Loss, But Lack of Safety Detail Is a Sticking Point
Novo Nordisk is developing the molecule for the treatment of obesity ... CagriSema, for example, combines semaglutide, the main pharmaceutical ingredient in the company’s approved obesity ...
Scientists find Ozempic may treat cancer, Alzheimer's and more. Is it hype or truly a "wonder drug?"
Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...
Yahoo Finance13d
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...
Yahoo Finance6d
Why Eli Lilly Stock Topped the Market Today
On Friday morning, Novo Nordisk unveiled the latest results from a clinical trial of CagriSema, an investigational drug leveraging the foundational semaglutide molecule used in Wegovy ...